Subject Index

AERD, see Aspirin exacerbated respiratory disease
AFRS, see Allergic fungal rhinosinusitis
Allergic fungal rhinosinusitis (AFRS)
diagnosis
eosinophilic mucin 16
fungal smear 17
imaging 16
nasal polyposis 16
type I hypersensitivity 15
epidemiology 14, 15
gene expression 17
management 18, 19, 143
modified endoscopic medial maxillectomy 152, 153
overview 14
pathophysiology 14
prognosis 19
protein expression 17, 18
Allergy, chronic rhinosinusitis role
endoscopic modified Lothrop procedure 154
inflammatory cytokines 71
overview 69–71
sinonasal epithelial barrier disruption 71, 72
Amphotericin B, outcome measures 163
Antimicrobial peptides, chronic rhinosinusitis
studies 74, 75
Aspirin exacerbated respiratory disease (AERD)
desensitization outcome measures 162
diagnosis 22–24
leukotriene role 106
management 24–26
pathophysiology 21, 22

B-cell
activation in chronic rhinosinusitis with nasal polyps
chemokine upregulation 51
complement elevation 51, 52
cytokine upregulation 49–51
evidence 52
antibodies in chronic rhinosinusitis with nasal polyps
autoantibodies 54, 55
immunoglobulin E response 52–54
Staphylococcus aureus enterotoxins 54
antibody isotypes 48
subsets 49
Carboxymethyl cellulose (CMC), implant materials 133, 134
CF, see Cystic fibrosis
Chordoma 9
Chronic rhinosinusitis with nasal polyps (CRSwNP), see also Allergic fungal rhinosinusitis; Aspirin exacerbated respiratory disease
B-cell activation, see B-cell classification 13, 14, 58
immunomodulator therapy 103–111
innate lymphoid cell studies, see Innate lymphoid cell
oral medications
antibiotics 141, 142
antifungals 142, 143
corticosteroids 139–141
leukotriene antagonists 143–145
P-glycoprotein role, see P-glycoprotein
surgery, see Endoscopic sinus surgery
T helper response 2, 103, 122
topical medications, see also Topical steroids delivery 115–117
head position effects 118
nasal anatomy 118
overview 114, 115
sinus surgery effects 118
Chronic rhinosinusitis without nasal polyps (CRSsNP), T helper response 2
Churg–Strauss syndrome (CSS) 7, 8
CMC, see Carboxymethyl cellulose
Computed tomography (CT)
allergic fungal rhinosinusitis 16
cystic fibrosis sinusitis 31, 32
nasal polyps 2–6, 10
Corticosteroids
chronic rhinosinusitis with nasal polyps management 139, 140
outcome measures 161
topical, see Topical steroids
CRSsNP, see Chronic rhinosinusitis without nasal polyps
CRSwNP, see Chronic rhinosinusitis with nasal polyps
CSS, see Churg–Strauss syndrome
CT, see Computed tomography
Cystic fibrosis (CF)
acquired cystic fibrosis transmembrane regulator deficiency
hypoxia 81, 82
management
ivacaflor 82
resveratrol 82, 83
Sinupret 83, 84
vitamin C 83
overview 79, 80
tobacco smoke 80, 81
genetics 29, 30
nasal polyps 13
pig model 32
rhinosinusitis
clinical features 29–31
endoscopy 31
epidemiology 79
imaging 31, 32
pathophysiology 32
treatment 32–35
Dacrocystocele 4, 5
Defensins, chronic rhinosinusitis studies 74, 75
Doxycycline, chronic rhinosinusitis with nasal polyps management 141, 162
Draf 3 frontal sinusotomy 153–155
Dupilumab, chronic rhinosinusitis with nasal polyps management 108, 109
E-cadherin, sinonasal epithelial barrier disruption in chronic rhinosinusitis 71, 72
Encephalocele 5
Endoscopic sinus surgery (ESS)
Draf 3 frontal sinusotomy 153–155
implants
biomaterials overview 132
carboxymethyl cellulose 133, 134
complications 135, 136
drug-eluting stents
MicroFlow Spacer 134
Nasopore 134, 135
Propel 135
Merocel 133
Merogel 133
nonabsorbable versus absorbable spacers 132, 133
Resolve Study implant 135
middle turbinate resection 149, 150
modified endoscopic medial maxillectomy 150–153
nasal polyp management 131
nasalisation 155, 156
outcome measures 163, 164
topical medication effects 118
ESS, see Endoscopic sinus surgery
Esthesioneuroblastoma 9
Glioma 5
GPA, see Granulomatosis with polyangiitis
Granulomatosis with polyangiitis (GPA) 8
Hemangioma 7
Hemangiopericytoma 7
Hypoxia, acquired cystic fibrosis transmembrane regulator deficiency 81, 82
IL-4, see Interleukin-4
IL-5, see Interleukin-5
IL-8, see Interleukin-8
IL-33, see Interleukin-33
ILC, see Innate lymphoid cell
Immunoglobulins, see B-cell
Implants, see Endoscopic sinus surgery
Innate lymphoid cell (ILC)
chronic rhinosinusitis with nasal polyps studies
prospects for study 65, 66
therapeutic targeting 64, 65
type 1 cells 63, 64
immunomodulation 41, 42
multidrug resistance role 41
steroid resistance role 128
structure 40
tissue distribution 40, 41
xenobiotic efflux 41
PROMs, see Patient reported outcome measures
Propel, drug-eluting stent 135
Radical ethmoidectomy 155, 156
Reslizumab, chronic rhinosinusitis with nasal polyps management 108
Resolve Study, implant 135
Resveratrol
acquired cystic fibrosis transmembrane regulator deficiency management 82, 83
cystic fibrosis management 34
Sinonasal irrigation
adverse events 116
distribution effectiveness 116
medications 116
Sinonasal Outcome Test-22 (SNOT-22) 159, 160
Sinupret, acquired cystic fibrosis transmembrane regulator deficiency management 83, 84
Smoking, acquired cystic fibrosis transmembrane regulator deficiency 80, 81
SNOT-22, see Sinonasal Outcome Test-22
Solitary chemosensory cell, see Taste receptors
Spray, see Nasal spray
Squamous cell carcinoma 8, 9
Staphylococcus aureus enterotoxins, antibodies in chronic rhinosinusitis with nasal polyps 54
Taste receptors
bitter taste receptors
ciliated cells of upper airway 93–96
polymorphisms in sinonasal disease 95, 96
immune function 92, 93
solitary chemosensory cell bitter and sweet receptors 96–99
TLRs, see Toll-like receptors
Toll-like receptors (TLRs), chronic rhinosinusitis studies 72–74
Topical steroids
benefits in chronic rhinosinusitis with nasal polyps 123, 124
nasal drops 117
outcome measures 160, 161
potency, bioavailability, and effectiveness 126
resistance 126–128
safety
dose exposure 124
eye 125
growth effects in children 125
hypothalamic-pituitary-adrenal axis suppression 124, 125
minor effects 126
mucosal atrophy 125, 126
systemic versus topical steroids 124
Toxic shock syndrome (TSS), nasal packing and stent association 135, 136
TSS, see Toxic shock syndrome
Vascular endothelial growth factor (VEGF), aspirin exacerbated respiratory disease pathophysiology 22
VEGF, see Vascular endothelial growth factor
Verapamil, steroid resistance treatment 128
Vitamin C, acquired cystic fibrosis transmembrane regulator deficiency management 83
VX-770, cystic fibrosis management 34
Zileuton, chronic rhinosinusitis with nasal polyps management 107, 145
ZO-1, see Zonula occludens-1
Zonula occludens-1 (ZO-1), sinonasal epithelial barrier disruption in chronic rhinosinusitis 71, 72